CD4 and neoplasm: However, beyond the utility of using CD1c (BDCA-1)+ myDC, CD141 (BDCA-3)+ myDC would also be of interest, because this subtype of myDC is likely more potent in cross-presenting tumor antigens and stimulating CD8+ CTL responses, as compared to CD1c (BDCA-1)+ myDC that are suspected to mainly stimulate CD4+ T-cell responses.